De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Advicenne Toekomstige groei
Future criteriumcontroles 6/6
Advicenne is forecast to grow earnings and revenue by 47.3% and 31.8% per annum respectively. EPS is expected to grow by 55.7% per annum. Return on equity is forecast to be 62.8% in 3 years.
Belangrijke informatie
47.3%
Groei van de winst
55.7%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 17.7% |
| Inkomstengroei | 31.8% |
| Toekomstig rendement op eigen vermogen | 62.8% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 01 Oct 2024 |
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -4 | -6 | -4 | 2 |
| 12/31/2025 | 5 | 9 | 9 | 9 | 2 |
| 12/31/2024 | 4 | -9 | -7 | -6 | 2 |
| 6/30/2024 | 3 | -9 | -6 | -5 | N/A |
| 3/31/2024 | 3 | -8 | -6 | -5 | N/A |
| 12/31/2023 | 3 | -7 | -7 | -6 | N/A |
| 9/30/2023 | 3 | -9 | -8 | -7 | N/A |
| 6/30/2023 | 3 | -10 | -8 | -8 | N/A |
| 3/31/2023 | 3 | -11 | -9 | -8 | N/A |
| 12/31/2022 | 3 | -11 | -9 | -9 | N/A |
| 9/30/2022 | 3 | -10 | -9 | -9 | N/A |
| 6/30/2022 | 4 | -9 | -9 | -9 | N/A |
| 3/31/2022 | 4 | -11 | -11 | -11 | N/A |
| 12/31/2021 | 4 | -12 | -13 | -13 | N/A |
| 9/30/2021 | 4 | -14 | -13 | -13 | N/A |
| 6/30/2021 | 4 | -15 | -15 | -14 | N/A |
| 3/31/2021 | 4 | -15 | -14 | -13 | N/A |
| 12/31/2020 | 3 | -15 | -12 | -12 | N/A |
| 9/30/2020 | 3 | -15 | -13 | -12 | N/A |
| 6/30/2020 | 3 | -15 | N/A | N/A | N/A |
| 3/31/2020 | 2 | -14 | N/A | N/A | N/A |
| 12/31/2019 | 3 | -14 | -10 | -9 | N/A |
| 9/30/2019 | 2 | -11 | N/A | N/A | N/A |
| 6/30/2019 | 2 | -8 | -11 | -11 | N/A |
| 3/31/2019 | 1 | -6 | -11 | -10 | N/A |
| 12/31/2018 | 1 | -5 | -10 | -10 | N/A |
| 9/30/2018 | 2 | -6 | N/A | N/A | N/A |
| 6/30/2018 | 2 | -7 | -7 | -6 | N/A |
| 3/31/2018 | 2 | -7 | N/A | -6 | N/A |
| 12/31/2017 | 3 | -6 | N/A | -6 | N/A |
| 9/30/2017 | 2 | -5 | N/A | -5 | N/A |
| 6/30/2017 | 2 | -4 | N/A | -5 | N/A |
| 3/31/2017 | 2 | -4 | N/A | -3 | N/A |
| 12/31/2016 | 2 | -4 | N/A | 0 | N/A |
| 12/31/2015 | 3 | -2 | N/A | N/A | N/A |
| 12/31/2014 | 2 | -2 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ALDVI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Winst versus markt: ALDVI is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: ALDVI is expected to become profitable in the next 3 years.
Omzet versus markt: ALDVI's revenue (31.8% per year) is forecast to grow faster than the French market (5.7% per year).
Hoge groei-inkomsten: ALDVI's revenue (31.8% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: ALDVI's Return on Equity is forecast to be very high in 3 years time (62.8%).